Journals / Türk Fertilite Dergisi / 2005 / Cilt: 13 - Sayı: 1

Effect of estrogen replacement therapy on lipid profile in hysterectomised women

Histerektomili kadınlarda östrojen replasman tedavisinin lipid profiline etkisi

Pages
78–83
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mean plasma total cholesterol and LDL-C concentrations were decreased (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to evaluate the ef¬fects of oral and transdermal estrogen replacement therapy (ERT) on serum lipid profile in healthy, postmenopausal women.
📊
Key Findings & Data:Gro¬up 1 (n=40) recieved oral conjugated equine estrogen, 0.625 mg/day, and Group 2 (n=40) transdermal 17 beta estradiol, 50 fug/day.
💡
Conclusion & Impact:Mean plasma total cholesterol and LDL-C concentrations were decreased (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to evaluate the ef¬fects of oral and transdermal estrogen replacement therapy (ERT) on serum lipid profile in healthy, postmenopausal women. Institution: Atatürk University, Faculty of Medicine, Department of Obstetrics and Gynecology, Erzurum Materials and Methods: Eighty healthy, hysterectomized, postmenopausal women were divided two groups. Gro¬up 1 (n=40) recieved oral conjugated equine estrogen, 0.625 mg/day, and Group 2 (n=40) transdermal 17 beta estradiol, 50 fug/day. Plasma concentrations of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low- density lipoprotein cholesterol (LDL-C), very low- density lipoprotein cholesterol (VLDL-C) and triglycerdes were measured at baseline and after 1 year of therapy. Results: There were no differences in the baseline value between two groups. Mean plasma total cholesterol and LDL-C concentrations were decreased (p

Özet

Amaç: Sağlıklı postmenapozal kadınlarda oral ve transdermal östrojen replasman tedavisinin etkilerini araş¬tırmak idi. Çalışmanın Yapıldığı Yer: Atatürk Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğuna Anabilim Dalı, Erzurum Materyal ve Metod: 80 sağlıklı histererektomize, postmenapozal kadın 2 gruba ayrıldı. Grup 1 (n=40) 0.625 mg/gün oral konjuge equin östrojen, Grup 2, (n=40) ise 50 /jg/gün 17 beta-estradiol salan transdermal östrojen aldı. Plazma total kolesterol, yüksek dansiteli lipoprotein kolesterol {HDL-Q, düşük dansiteli lipoprotein kolesterol (LDL-C), çok düşük dansiteli lipoprotein kolesterol (VLDL-C) ve trigliserit konsantrasyonları bazal ve tedavinin 1. yılında ölçüldü. Bulgular: İki grup arasında bazal değerlendirmede farklılık tespit edilmedi. Oral östrojen grubunda tedavinin 1. yılı sonunda ortalama total kolesterol ve LDL-C konsant¬rasyonları azalırken (sırasıyla, p

🔖

Cite This Article

İSAOĞLU, Ü., KADANALI, S., İNGEÇ, M., KUMTEPE, Y., BÖREKÇİ, B. (2022). Effect of estrogen replacement therapy on lipid profile in hysterectomised women. Türk Fertilite Dergisi, Cilt: 13 - Sayı: 1, 78–83. https://ajindex.com/articles/623329

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Tikkanen MJ. Estrogens, progestins and lipid metabolism. Maturitas 1996; 23: 51-55
  2. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981; 139: 47-51
  3. Lip GY, Blann AD, Jones AF, Beevers DG. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997; 134: 64-771
  4. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83-90
  5. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-941
  6. Fukami K, Koike K, Hirota K, Yoshikawa H, Miyake A. Perimenopausal changes in serum lipids and lipoproteins: a 7- year longitudinal study. Maturitas 1995; 22: 193-197
  7. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002; 137: 273-284
  8. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-374
  9. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037
  10. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613
  11. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57
  12. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the WomenÕs Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the WomenÕs Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333
  13. Anderson GL, Limacher M, Assaf AR, et al; WomenÕs Health Initiative Steering Committee. Effects of con